Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT NASDAQ:CVAC NASDAQ:GPCR NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACVACCureVac$5.36-0.2%$5.43$2.37▼$5.72$1.20B2.53608,253 shs300,977 shsGPCRStructure Therapeutics$19.71-1.8%$18.87$13.22▼$45.37$1.11B-1.88831,856 shs6.06 million shsOLMAOlema Pharmaceuticals$6.29-2.8%$5.03$2.86▼$13.93$374.74M1.92424,996 shs1.82 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%-3.73%CVACCureVac-0.19%-0.37%-1.83%+20.18%+75.16%GPCRStructure Therapeutics-1.84%+3.74%+17.46%-8.20%-48.36%OLMAOlema Pharmaceuticals-2.78%+9.58%+16.27%+49.41%-44.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ACVACCureVac4.5111 of 5 stars3.15.00.04.93.80.01.3GPCRStructure Therapeutics2.3792 of 5 stars3.51.00.00.03.01.70.6OLMAOlema Pharmaceuticals2.0674 of 5 stars3.30.00.00.03.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/ACVACCureVac 2.20Hold$6.8327.49% UpsideGPCRStructure Therapeutics 3.00Buy$75.71284.14% UpsideOLMAOlema Pharmaceuticals 2.67Moderate Buy$24.00281.56% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, GPCR, CVAC, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.008/14/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$28.00 ➝ $29.008/12/2025OLMAOlema PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $21.008/11/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell8/7/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.008/7/2025GPCRStructure TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$92.00 ➝ $90.008/7/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$89.00 ➝ $87.006/26/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.506/23/2025GPCRStructure TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.006/23/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$89.006/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74CVACCureVac$579.18M2.08$0.87 per share6.15$2.97 per share1.80GPCRStructure TherapeuticsN/AN/AN/AN/A$13.40 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ACVACCureVac$175.50M$0.965.58N/AN/A38.21%29.57%25.41%11/11/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$1.05N/AN/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)Latest OLMA, GPCR, CVAC, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025CVACCureVac-$0.15-$0.30-$0.15-$0.30$4.27 million$1.41 million8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/6/2025Q2 2025GPCRStructure Therapeutics-$0.28-$0.36-$0.08-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59CVACCureVac0.056.176.16GPCRStructure TherapeuticsN/A20.4820.48OLMAOlema Pharmaceuticals0.0111.0911.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%CVACCureVac17.26%GPCRStructure Therapeutics91.78%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%CVACCureVacN/AGPCRStructure Therapeutics5.60%OLMAOlema Pharmaceuticals16.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableCVACCureVac880224.34 millionN/AOptionableGPCRStructure Therapeutics13657.60 million54.37 millionOptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableOLMA, CVAC, CALT, and GPCR HeadlinesRecent News About These CompaniesPfizer collaboration with Olema may spark future bidding war - analystSeptember 3 at 5:11 PM | msn.comOlema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement PlanSeptember 3 at 4:51 PM | quiverquant.comQOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3 at 4:30 PM | globenewswire.comOlema Pharmaceuticals, Inc. $OLMA Shares Sold by Paradigm Biocapital Advisors LPSeptember 2 at 7:09 AM | marketbeat.comOlema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerSeptember 2 at 7:00 AM | globenewswire.comNuveen LLC Acquires New Holdings in Olema Pharmaceuticals, Inc. $OLMASeptember 2 at 3:31 AM | marketbeat.comWellington Management Group LLP Reduces Stake in Olema Pharmaceuticals, Inc. $OLMAAugust 31, 2025 | marketbeat.com325,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Purchased by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comCandriam S.C.A. Decreases Holdings in Olema Pharmaceuticals, Inc. $OLMAAugust 25, 2025 | marketbeat.comOlema Oncology to Participate in Upcoming Investor ConferencesAugust 20, 2025 | globenewswire.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 17, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysAugust 16, 2025 | marketbeat.comCitigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) StockAugust 13, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Posts Earnings ResultsAugust 12, 2025 | marketbeat.comOlema Oncology Reports Second Quarter 2025 Financial and Operating ResultsAugust 11, 2025 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comH.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials AdvanceMay 30, 2025 | msn.comOlema Pharmaceuticals Selects 90 mg Palazestrant Dose for Phase 3 OPERA-01 and OPERA-02 TrialsMay 29, 2025 | nasdaq.comOlema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual MeetingMay 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOLMA, CVAC, CALT, and GPCR Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 09/2/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.CureVac NASDAQ:CVAC$5.36 -0.01 (-0.19%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$5.36 0.00 (0.00%) As of 09/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Structure Therapeutics NASDAQ:GPCR$19.71 -0.37 (-1.84%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$20.30 +0.59 (+2.99%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Olema Pharmaceuticals NASDAQ:OLMA$6.29 -0.18 (-2.78%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$6.30 +0.01 (+0.16%) As of 09/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
